Press release
Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 28th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 8 through 15, 2023. The following abstracts were posted to the EHA website on May 11, 2023, 10:00 a.m. Eastern time. Clinical Presentation “KER-050 treatment improved markers of erythropoietic activity and hematopoiesis over six months which resulted in hematological responses across a broad, lower-risk MDS population” Abstract Code: S166Session Title: s417 MPN and MDS: Targeting red cells and plateletsSession Date and Time: June 9, 2023; 8:45 a.m. - 10:00 a.m. Eastern time Preclinical Presentations “A modified activin receptor type II ligand trap RKER-050 restored erythropoiesis in a mouse model of myelofibrosis” Abstract Code: P992Session Title: Poster sessionSession Date and Time: June 9, 2023; 12:00 p.m. – 1:00 p.m. Eastern time “Combining ALK2 inhibition with a modified activin receptor IIA ligand trap provided additive benefits in resolving anemia in a mouse model of anemia of inflammation” Abstract Code: P1488Session Title: Poster sessionSession Date and Time: June 9, 2023; 12:00 p.m. – 1:00 p.m. Eastern time About KER-050 Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet me...